Advertisement

Drugs & Aging

, Volume 18, Issue 7, pp 495–505 | Cite as

Orthostatic Hypotension in Patients with Parkinson’s Disease

Pathophysiology and Management
  • Jean-Michel SenardEmail author
  • Christine Brefel-Courbon
  • Olivier Rascol
  • Jean-Louis Montastruc
Therapy in Practice

Abstract

Orthostatic hypotension is common in elderly patients, and is now considered to be an important prognostic factor for cognitive decline and mortality. In patients with Parkinson’s disease, the prevalence of symptomatic orthostatic hypotension may be as high as 20%. Two factors could explain this high prevalence. First, dopaminergic drugs may induce or worsen orthostatic hypotension. Secondly, Parkinson’s disease is a cause of primary autonomic failure with an involvement of the peripheral autonomic system as shown by the ubiquitous distribution of Lewy bodies and reduced iobenguane [metaiodobenzylguanidine (MIBG)] cardiac uptake. These pathological and pharmacological characteristics clearly differentiate autonomic failure of Parkinson’s disease from multiple system atrophy. If autonomic abnormalities appear to be present from the first stage of the disease, early onset (within the first year) of symptomatic orthostatic hypotension in the course of parkinsonism can be considered as an exclusion criteria for idiopathic Parkinson’s disease.

No specific clinical trials have evaluated the effects of antihypotensive drugs in patients with Parkinson’s disease and thus no specific therapeutic strategy can be recommended. The management of orthostatic hypotension in patients with Parkinson’s disease should always start with patient education and nonpharmacological treatment. Drug therapy should be reserved for symptomatic patients who do not get benefit from nonpharmacological management. Among the available drugs, α1-adrenergic agonists (mainly midodrine) or plasma volume expanders (mainly fludrocortisone) are the most frequently used. There are also some drugs that are currently investigational such as yohimbine and droxidopa. Other drugs such as desmopressin or octreotide may be of interest in some situations. Domperidone is widely used in patients with parkinsonism with no proven effect on orthostatic hypotension.

Keywords

Orthostatic Hypotension Multiple System Atrophy Yohimbine Ambulatory Blood Pressure Monitoring Domperidone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ensrud KE, Nevitt MC, Yunis C, et al. Postural hypotension and postural dizziness in elderly women: the study of osteoporotic fractures. Arch Intern Med 1992; 152: 1058–64PubMedCrossRefGoogle Scholar
  2. 2.
    Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in the older adults: the cardiovascular health study. Hypertension 1992; 19: 508–19PubMedCrossRefGoogle Scholar
  3. 3.
    Raíha I, Luutonen S, Piha J, et al. Prevalence predisposing factors, and prognosis importance of postural hypotension. Arch Intern Med 1995; 155: 930–5PubMedCrossRefGoogle Scholar
  4. 4.
    Elmstahl S, Rosen I. Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women. Dement Geriatr Cogn Disord 1997; 8: 180–7PubMedCrossRefGoogle Scholar
  5. 5.
    Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu heart program. Circulation 1998; 98: 2290–5PubMedCrossRefGoogle Scholar
  6. 6.
    Luukinen H, Koski K, Laippala P, et al. Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch Intern Med 1999 Feb; 159: 273–80PubMedCrossRefGoogle Scholar
  7. 7.
    Korczyn AD. Autonomic nervous system disturbances in Parkinson’ s disease. In: Streifler MB, Korczyn AD, Melamed E, et al., editors. Advances in neurology: Parkinson’s disease: anatomy, pathology and therapy. Vol 53. New York: Raven Press, 1990: 463–8Google Scholar
  8. 8.
    Consensus Committee of the American Autonomic Society and the American Academy of Neurolgy. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Neurology 1996; 46: 1470CrossRefGoogle Scholar
  9. 9.
    Caine SE, Alsop K, MacMahon M. Overlooking orthostatic hypotension with routine blood pressure equipment. Lancet 1998; 352: 458PubMedCrossRefGoogle Scholar
  10. 10.
    Senard JM, Rascol O, Rascol A, et al. Ambulatory blood pressure monitoring in the study of autonomic dysfunction. In: Korczyn AD, editor. Handbook of autonomic nervous system dysfunction. Marcel Dekker: New York, 1995: 413–25Google Scholar
  11. 11.
    Bannister R, Mathias CJ. Introduction and classification of autonomic disorders. In: Mathias CJ, Bannister R, editors. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. Oxford: Oxford University Press, 1999: xvii–xxiiGoogle Scholar
  12. 12.
    Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathological study. Neurology 1992; 42: 1142–6PubMedCrossRefGoogle Scholar
  13. 13.
    Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998; 74: 189–92PubMedGoogle Scholar
  14. 14.
    Fichefet JP, Sternon JE, Franken L, et al. Etude anatomoclinique d’un cas d’hypotension orthostatique idiopathique. Acta Cardiol 1965; 20: 332–48PubMedGoogle Scholar
  15. 15.
    van Dijk JG, Haan J, Zwinderman K, et al. Autonomic nervous system dysfunction in Parkinson’s disease: relationship with age, medication, duration and severity. J Neurol Neurosurg Psychiatry 1993; 56: 1090–5PubMedCrossRefGoogle Scholar
  16. 16.
    Wennings GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999; 67: 620–3CrossRefGoogle Scholar
  17. 17.
    Senard JM, Raï S, Lapeyre-Mestre M. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 63: 584–9PubMedCrossRefGoogle Scholar
  18. 18.
    Wakabayashi K, Takahashi H, Ohama E, et al. Lewy bodies in thevisceral autonomic nervous system in Parkinson’s disease. In: Narabayashi H, Nagatsu T, Yanagisawa N, et al., editors. Advances in neurology. New York: Raven Press, 1993: 609–12Google Scholar
  19. 19.
    Senard JM, Valet P, Durrieu G, et al. Adrenergic supersensitivity in parkinonsonians wih orthostatic hypotension. Eur J Clin Invest 1990; 20: 613–9PubMedCrossRefGoogle Scholar
  20. 20.
    Kimber JR, Watson L, Mathias CJ. Distinction of Parkinson’s disease from multiple system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997; 349: 1877–81PubMedCrossRefGoogle Scholar
  21. 21.
    Senard JM, Rascol O, Durrieu G, et al. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson’s disease or multiple system atrophy. Clin Neuropharmacol 1993; 16: 70–6PubMedCrossRefGoogle Scholar
  22. 22.
    Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999; 53: 1020–5PubMedCrossRefGoogle Scholar
  23. 23.
    Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000; 41: 71–7PubMedGoogle Scholar
  24. 24.
    Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 1997; 17: 105–18PubMedCrossRefGoogle Scholar
  25. 25.
    Montastruc JL, Pelat M, Verwaerde P, et al. Fluoxetine in orthostatic hypotension of Parkinson’s disease: a clinical and experimental pilot study. Fundam Clin Pharmacol 1998; 12: 398–402PubMedCrossRefGoogle Scholar
  26. 26.
    Camerlingo M, Ferraro B, Cazzaniga GC, et al. Cardiovascular reflexes in Parkinson’s disease: long term effects of levodopa treatment on de novo patients. Acta Neurol Scand 1990; 81: 346–8PubMedCrossRefGoogle Scholar
  27. 27.
    Kujawa K, Leurgans S, Raman R, et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease. Arch Neurol 2000 Oct; 57: 1461–3PubMedCrossRefGoogle Scholar
  28. 28.
    Turkka J, Suominen K, Tolonen U, et al. Selegiline diminishes cardiovascular autonomic responses in Parkinson’s disease. Neurology 1997; 48: 662–7PubMedCrossRefGoogle Scholar
  29. 29.
    Lyytinen J, Sovijärvi A, Kaakkola S, et al. The effect of catachol-o-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson’s disease. Clin Neuropharmacol 2001; 24: 50–7PubMedCrossRefGoogle Scholar
  30. 30.
    Bannister R, Mathias CJ. Management of postural hypotension. In: Mathias CJ, Bannister R, editors. Autonomic failure: a text book of clinical disorders of the autonomic nervous system. Oxford: Oxford University Press, 1999: 342–56Google Scholar
  31. 31.
    Biagoni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet 1987; 21: 1170–5CrossRefGoogle Scholar
  32. 32.
    Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, cross-over trial. Neurology 1999; 53: 2151–7PubMedCrossRefGoogle Scholar
  33. 33.
    Senard JM, Rascol O, Rascol A, et al. Lack of yohimbine effect on ambulatory blood pressure recording: a double-blind cross-over trial in parkinsonians with orthostatic hypotension. Fundam Clin Pharmacol 1993; 7: 465–70PubMedGoogle Scholar
  34. 34.
    Kuchel O, Buu NT, Gutkowska J, et al. Treatment of severe orthostatic hypotension by metoclopramide. Ann Intern Med 1980; 93: 841–3PubMedGoogle Scholar
  35. 35.
    Beretta-Piccoli C, Weidmann P. Metoclopramide alone or combined with flurbiprofen in the treatment of orthostatic hypotension associated with diabetes mellitus. Klin Wochenschr 1982; 60: 863–5PubMedCrossRefGoogle Scholar
  36. 36.
    Lopes de Faria S, Zanella MT, Andriolo A, et al. Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Clin Pharmacol Ther 1988; 44: 670–4PubMedCrossRefGoogle Scholar
  37. 37.
    Montastruc JL, Chamontin B, Senard JM, et al. Domperidone in the management of orthostatic hypotension. Clin Neuropharmacol 1985; 8: 191–2PubMedCrossRefGoogle Scholar
  38. 38.
    Capria A, Attanasio A, Quatrana M, et al. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson’s disease. Clin Neuropharmacol 1989; 12: 331–8PubMedCrossRefGoogle Scholar
  39. 39.
    McClellan KJ, Wiseman LR, Wilde MI. Midodrine: a review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 1998 Jan; 12(1): 76–86PubMedCrossRefGoogle Scholar
  40. 40.
    Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med 1993 Jul; 95: 38–48PubMedCrossRefGoogle Scholar
  41. 41.
    Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. JAMA 1997 Apr; 277(13): 1046–51PubMedCrossRefGoogle Scholar
  42. 42.
    Desboeuf K, Senard JM, Pavy-Le-Traon A, et al. Clinical practice survey of midodrine prescribing in a universitary hospital. Therapie 2000; 55: 613–7PubMedGoogle Scholar
  43. 43.
    Miller E, Wiener L, Bloomfield D. Etilefrine in the treatment of levodopa-induced orthostatic hypotension. Arch Neurol 1973; 29(2): 99–103PubMedCrossRefGoogle Scholar
  44. 44.
    Biaggioni I, Onrot J, Stewart CK, et al. The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA 1987; 258: 236–9PubMedCrossRefGoogle Scholar
  45. 45.
    Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833–8PubMedCrossRefGoogle Scholar
  46. 46.
    Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826–32PubMedCrossRefGoogle Scholar
  47. 47.
    Biaggioni I, Robertson D, Krantz S, et al. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 1994 Aug; 121(3): 181–6PubMedGoogle Scholar
  48. 48.
    Ten Harkel AD, van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position and in combination with fludrocortisone. J Intern Med 1992; 232: 139–45PubMedCrossRefGoogle Scholar
  49. 49.
    Hoehn MM. Levodopa-induced postural hypotension: treatment with fludrocortisone. Arch Neurol 1975 Jan; 32(1): 50–1PubMedCrossRefGoogle Scholar
  50. 50.
    Hakamäki T, Rajala T, Lehtonen A. Ambulatory 24-hour blood pressure recordings in patients with Parkinson’s disease with or without fludrocortisone. Int J Clin Pharmacol Ther 1998; 36(7): 367–70PubMedGoogle Scholar
  51. 51.
    Takaku F, Hirashima K, Okinaka S. Effect of bilateral section of splanchnic nerve on erythropoiesis. Nature 1961; 191: 500–1PubMedCrossRefGoogle Scholar
  52. 52.
    Hoeldtke RD, Streeten DHP. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 1993 Aug; 329(9): 611–5PubMedCrossRefGoogle Scholar
  53. 53.
    Nair B, Leitch J. Erythropoietin treatment for postural hypotension from autonomic dysfunction. Aust N Z J Med 1996; 26: 859–60PubMedCrossRefGoogle Scholar
  54. 54.
    Thomaides T, Bleasdale-Barr K, Chaudhuri RK, et al. Cardiovascular and hormonal responses to liquid food challenge in idiopathic Parkinson’s disease, multiple system atrophy and pure autonomic failure. Neurology 1993; 43: 900–4PubMedCrossRefGoogle Scholar
  55. 55.
    Chaudhuri KR, Ellis C, Love-Jones S, et al. Postprandial hypotension and parkinsonian state in Parkinson’s disease. Mov Disord 1997; 12(6): 877–84PubMedCrossRefGoogle Scholar
  56. 56.
    Mathias CJ. Postprandial hypotension: pathophysiological mechanisms and clinical implications in different disorders. Hypertension 1991; 18: 694–704PubMedCrossRefGoogle Scholar
  57. 57.
    Onrot J, Goldberg MR, Biaggioni I, et al. Haemodynamic and humoral effects of caffeine in autonomic failure: therapeutic implications for postprandial hypotension. N Engl J Med 1985; 313: 549–54PubMedCrossRefGoogle Scholar
  58. 58.
    Lipsitz LA, Jansen RWMM, Connelly CM, et al. Haemodynamic and neurohumoral effects of caffeine in elderly patients with symptomatic postprandial hypotension: a double-blind, randomized, placebo-controlled study. Clin Sci 1994; 87: 259–67PubMedGoogle Scholar
  59. 59.
    Hoeldtke RD, O’Dorisio TM, Boden G. Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995. Lancet 1986; 2: 602–5PubMedCrossRefGoogle Scholar
  60. 60.
    Jansen RWMM, Peeters TL, Lenders JWM, et al. Somatostain analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in the elderly. J Clin Endocrinol Metab 1989; 68: 752–6PubMedCrossRefGoogle Scholar
  61. 61.
    Bordet R, Benhadjali J, Libersa C, et al. Octreotide in the management of orthostatic hypotension in multiple system atrophy: pilot trial of chronic administration. J Clin Neuropharmacol 1994; 17: 380–3Google Scholar
  62. 62.
    Hoeldtke RD, Horvath GG, Bryner KD, et al. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab 1998; 83: 339–43PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Jean-Michel Senard
    • 1
    Email author
  • Christine Brefel-Courbon
    • 1
  • Olivier Rascol
    • 1
  • Jean-Louis Montastruc
    • 1
  1. 1.Laboratory of Medical and Clinical Pharmacology, INSERM U317, Faculty of MedicinePaul Sabatier UniversityToulouse cedexFrance

Personalised recommendations